Fredun Pharmaceuticals Ltd – Company Report
1. Company Overview
Fredun Pharmaceuticals Ltd, established in 1987 and headquartered in Mumbai, Maharashtra, is a leading Indian manufacturer specializing in pharmaceutical formulations, dietary supplements, nutraceuticals, and healthcare products. With decades of experience, the company has built a strong reputation both domestically and abroad, serving leading pharmaceutical companies and markets across Africa, South East Asia, CIS countries, and Latin America. Fredun is guided by an experienced board, including Chairman Fredun Nariman Medhora, and is classified as a public company in the pharmaceutical manufacturing space. The company upholds international quality and compliance standards, operating with a robust infrastructure and a global footprint.
- Incorporated: December 8, 1987
- Headquarters: Mumbai, Maharashtra, India
- Core Focus: Pharmaceutical manufacturing, dietary supplements, nutraceuticals, animal and healthcare products
- Key Leadership: Fredun Nariman Medhora (Chairman)
- Employees: Approximately 200–500
- Corporate Status: Public company
- Authorized Share Capital: ₹10 crore
- Paid-up Capital: ₹4.72 crore
2. Products and Services
Fredun Pharmaceuticals Ltd boasts a diverse portfolio of products and services for a wide range of health and wellness needs:
Pharmaceutical Formulations
- Allopathic products: tablets, capsules, syrups, ointments, injectables
- Therapeutic categories include:
- Analgesics, Antacids, Anthelmintics
- Antibacterials, Antidiabetics, Anti-inflammatories
- Antimalarials, Anticoagulants, Anticonvulsants
- Antidiarrheals, Antidepressants, Antifungals
- Antihistamines, Antihypertensives, Antivirals
- Bone modulators, Bronchodilators, Cardiovascular drugs
- Diuretics, Impotence drugs, Laxatives, Multivitamin formulations
Healthcare & Nutraceuticals
- Dietary/herbal supplements
- Multivitamin and mineral blends
- Amino acid complexes
- Targeted wellness formulations
Animal and Aqua Health Products
- Veterinary and aquaculture-specific drugs and supplements
Surgical & Personal Healthcare Products
- IV fluids
- Syringes, infusion sets, surgical gloves
- Disposables, cotton rolls
APIs and Custom Services
- Active Pharmaceutical Ingredients (APIs)
- Direct compressible granules
- Contract manufacturing & custom formulation services
Distribution & Global Reach
- Products licensed internationally across regulatory zones
- Major export markets: South East Asia, Africa, CIS, and Latin America
- Combination of proprietary and generic brands
Notable Brands
- Aclofre-P
- Srimet
- H-Cure
- Nefin 20 SR
- Additional in-house formulations
3. Recent News and Financial Performance
Expansion into Pet Care Market
- March 12, 2025: Fredun Pharmaceuticals Limited, a leading pharmaceutical and healthcare solutions provider for veterinary applications, has entered the large animal veterinary segment under its FREOSSI Large Animals brand. The company has launched two new products, Freossi Tone+ and Freossi Power, aimed at addressing common health issues in livestock.
- October 13, 2025: Fredun Pharmaceuticals launches Snacky Jain pet food, free from meat and root vegetables. Despite being entirely plant-based, Fredun claims that Snacky Jain “delivers essential nutrients to support superior immunity, digestion, bone health, and energy in pets.
- October 9, 2025: Fredun Pharmaceuticals Limited (FPL) has acquired Wagr.ai, a pet tech platform, marking its entry into India's pet care sector. The zero-cash transaction gives FPL a 78% stake via a subsidiary. FPL plans to relaunch Wagr.ai as a neutral online marketplace for pet products and services in Q4 FY 2025-26.
- July 2, 2025: Fredun Pharmaceuticals Limited , a diversified global healthcare company,Fredun Retail Private Limited (FRPL), has taken a significant step toward expanding its consumer-centric portfolio with the acquisition of a controlling interest in One Pet Stop Private Limited.
International Orders & Expansion
- February 12, 2024: Secured ₹28 crore in export orders from SEA markets
- November 28, 2022: The Company received one-year contract worth ₹65 crores from a Southeast Asian country for Pharma exports.The Company further signed a contract for specialized DC granules for various therapeutic end uses. The annual contract is worth ₹25 crores and has the potential to go up to ₹40 crores from second year onwards.
Government Tenders
- April 9, 2025: Awarded ₹15–18 crore contract from Tamil Nadu Medical Services Corporation (TNMSC). Contract for 14-month supply of essential medicines starting FY26
Quarterly Highlights (Q4 FY2025):
- Net Sales: ₹165.44 crore (+40.16% YoY)
- PAT: ₹7.07 crore (+32.6% YoY)
- Net Profit Margin: 4.22%
- EBIT Margin: 9.67%
4. Financial Performance (FY2025)
| Metric | FY2025 |
|---|---|
| Revenue from Operations | ₹456 crore |
| Net Profit | ₹19.74 crore |
| Operating Profit | ₹55 crore |
| Operating Profit Margin | 12% |
| EPS | ₹41.81 |